Hansa Biopharma announced the closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA Hansa Biopharma AB and SERB S.A. announced that the required regulatory approvals have been obtained and that the previously announced €115 million exclusive licensing transaction with SERB has closed. The company also announced that Maria Törnsén, […]
Here’s a novel thought: could the science that has enabled us to develop obesity drugs, be repurposed to help people put on weight? Now, the vast majority of us don’t, of course, need to put on weight. But some people do – notably many individuals with eating disorders such as anorexia nervosa. In a ‘Perspectives’ paper recently published in the New England Journal of Medicine, and an […]
With the Anglonordic Life Science Conference last week, BioEquity next week, ASGCT Annual meeting and LSX Nordic Congress around the corner, it is a good time to practice your pitching. Funds are open and now is the time to foster those new and old connections. Read on to discover what has happened this week and […]
Biotechs are becoming increasingly cautious about what they publish in scientific journals. The growing worry is that other companies, often based in China, will take the freshly published information and run with it – and go on to develop a target or very early stage drug much faster than the originator. This was a subject raised last week on a panel at the Anglonordic Life Science Conference in London, by Dr Adi Hoess, CEO […]
A profoundly positive response from Anglonordic attendees with hands shaken, conversations started and potential deals in the works. The main takeaway was the benefit of it being a ‘boutique’ event, meaning everyone could make the most of the 1:1 partnering, pitch presentations, and networking breaks. Keep reading to hear more about what’s been happening this […]
